Insider Selling: CeriBell (NASDAQ:CBLL) Director Sells 32,728 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL) Director William Burke sold 32,728 shares of the firm’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $22.02, for a total transaction of $720,670.56. Following the transaction, the director directly owned 17,391 shares in the company, valued at approximately $382,949.82. This represents a 65.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

CeriBell Stock Performance

Shares of CBLL traded up $0.23 during mid-day trading on Thursday, hitting $20.41. 368,478 shares of the company’s stock were exchanged, compared to its average volume of 314,351. The stock’s 50-day simple moving average is $13.98 and its 200-day simple moving average is $14.46. CeriBell, Inc. has a 52 week low of $10.01 and a 52 week high of $32.75. The company has a quick ratio of 12.25, a current ratio of 12.65 and a debt-to-equity ratio of 0.12. The firm has a market cap of $757.21 million, a price-to-earnings ratio of -13.52 and a beta of 1.35.

CeriBell (NASDAQ:CBLL) last released its earnings results on Tuesday, November 4th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.06. CeriBell had a negative return on equity of 29.63% and a negative net margin of 63.35%.The firm had revenue of $22.59 million during the quarter, compared to the consensus estimate of $21.78 million. On average, equities research analysts expect that CeriBell, Inc. will post -2.46 EPS for the current year.

Institutional Investors Weigh In On CeriBell

Several large investors have recently modified their holdings of the company. Tower Research Capital LLC TRC raised its stake in CeriBell by 353.8% during the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after buying an additional 1,801 shares during the last quarter. Ameritas Investment Partners Inc. grew its holdings in CeriBell by 97.5% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock worth $48,000 after acquiring an additional 1,256 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of CeriBell in the 3rd quarter worth about $33,000. Police & Firemen s Retirement System of New Jersey raised its position in shares of CeriBell by 161.0% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 5,677 shares of the company’s stock worth $106,000 after acquiring an additional 3,502 shares in the last quarter. Finally, New York State Common Retirement Fund lifted its stake in shares of CeriBell by 148.6% in the 2nd quarter. New York State Common Retirement Fund now owns 8,700 shares of the company’s stock valued at $163,000 after purchasing an additional 5,200 shares during the period.

Wall Street Analyst Weigh In

Several analysts recently issued reports on CBLL shares. Raymond James Financial initiated coverage on shares of CeriBell in a research report on Tuesday, October 21st. They set a “strong-buy” rating and a $19.00 price target on the stock. TD Cowen decreased their price target on shares of CeriBell from $36.00 to $20.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th. Weiss Ratings reiterated a “sell (e+)” rating on shares of CeriBell in a research note on Wednesday, October 8th. JPMorgan Chase & Co. cut their price target on CeriBell from $21.00 to $17.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. Finally, Cowen reissued a “buy” rating on shares of CeriBell in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $25.17.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.